Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis

Background: As an antidiabetic agent, sotagliflozin was recently approved for heart failure (HF). However, its cardiovascular benefits in type 2 diabetic mellitus (T2DM) patients with HF or cardiovascular (CV) risk factors have not been systematically evaluated. The aim of this study is to evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiyifan, Zhu, Chenyang, Liang, Jingru, Hu, Jiarong, Liu, Haiyang, Wang, Zihan, Guan, Ruifang, Chow, Junwei, Yan, Shiwei, Li, Longzhou, Ma, Fuyan, Ma, Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691547/
https://www.ncbi.nlm.nih.gov/pubmed/38044937
http://dx.doi.org/10.3389/fphar.2023.1303694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691547/
https://www.ncbi.nlm.nih.gov/pubmed/38044937
http://dx.doi.org/10.3389/fphar.2023.1303694

Ejemplares similares